Search

Your search keyword '"Malania Wilson"' showing total 3 results
Start Over Author "Malania Wilson"
3 results on '"Malania Wilson"'

1. Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines

Author

Li Wang, Markus H. Kainulainen, Nannan Jiang, Han Di, Gaston Bonenfant, Lisa Mills, Michael Currier, Punya Shrivastava-Ranjan, Brenda M. Calderon, Mili Sheth, Brian R. Mann, Jaber Hossain, Xudong Lin, Sandra Lester, Elizabeth A. Pusch, Joyce Jones, Dan Cui, Payel Chatterjee, M. Harley Jenks, Esther K. Morantz, Gloria P. Larson, Masato Hatta, Jennifer L. Harcourt, Azaibi Tamin, Yan Li, Ying Tao, Kun Zhao, Kristine Lacek, Ashley Burroughs, Wei Wang, Malania Wilson, Terianne Wong, So Hee Park, Suxiang Tong, John R. Barnes, Mark W. Tenforde, Wesley H. Self, Nathan I. Shapiro, Matthew C. Exline, D. Clark Files, Kevin W. Gibbs, David N. Hager, Manish Patel, Alison L. Halpin, Laura K. McMullan, Justin S. Lee, Hongjie Xia, Xuping Xie, Pei-Yong Shi, C. Todd Davis, Christina F. Spiropoulou, Natalie J. Thornburg, M. Steven Oberste, Vivien G. Dugan, SSEV Bioinformatics Working Group, David E. Wentworth, and Bin Zhou

Subjects
Science
Abstract

Emerging SARS-CoV-2 variants raise concerns on immune evasion. Here, the authors evaluate the neutralization efficiency of COVID-19 mRNA vaccinee sera against representative viruses of 13 WHO-designated SARS-CoV-2 variants of concern/interest.

Published
2022
Full Text
View/download PDF

2. Susceptibility to SARS-CoV-2 of Cell Lines and Substrates Commonly Used to Diagnose and Isolate Influenza and Other Viruses

Author

Li Wang, Xiaoyu Fan, Gaston Bonenfant, Dan Cui, Jaber Hossain, Nannan Jiang, Gloria Larson, Michael Currier, Jimma Liddell, Malania Wilson, Azaibi Tamin, Jennifer Harcourt, Jessica Ciomperlik-Patton, Hong Pang, Naomi Dybdahl-Sissoko, Ray Campagnoli, Pei-Yong Shi, John Barnes, Natalie J. Thornburg, David E. Wentworth, and Bin Zhou

Subjects
angiotensin-converting enzyme 2, ACE2, cell lines, coronavirus disease, COVID-19, influenza, Medicine, Infectious and parasitic diseases, RC109-216
Abstract

Co-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other viruses has been reported. We evaluated cell lines commonly used to isolate viruses and diagnose related diseases for their susceptibility to SARS-CoV-2. Although multiple kidney cell lines from monkeys were susceptible to SARS-CoV-2, we found many cell types derived from humans, dogs, minks, cats, mice, and chicken were not. We analyzed MDCK cells, which are most commonly used for surveillance and study of influenza viruses, and found that they were not susceptible to SARS-CoV-2. The low expression level of the angiotensin converting enzyme 2 receptor and lower receptor affinity to SARS-CoV-2 spike, which could be overcome by overexpression of canine angiotensin converting enzyme 2 in trans, strengthened the cellular barrier to productive infection. Moreover, a D614G mutation in the spike protein did not appear to affect SARS-CoV-2 cell tropism. Our findings should help avert inadvertent propagation of SARS-CoV-2 from diagnostic cell lines.

Published
2021
Full Text
View/download PDF

3. Bivalent mRNA vaccine improves antibody-mediated neutralization of many SARS-CoV-2 Omicron lineage variants

Author

Nannan Jiang, Li Wang, Masato Hatta, Chenchen Feng, Michael Currier, Xudong Lin, Jaber Hossain, Dan Cui, Brian R. Mann, Nicholas A. Kovacs, Wei Wang, Ginger Atteberry, Malania Wilson, Reina Chau, Kristine A. Lacek, Clinton R. Paden, Norman Hassell, Benjamin Rambo-Martin, John R. Barnes, Rebecca J. Kondor, Wesley H. Self, Jillian P. Rhoads, Adrienne Baughman, James D. Chappell, Nathan I. Shapiro, Kevin W. Gibbs, David N. Hager, Adam S. Lauring, Diya Surie, Meredith L. McMorrow, Natalie J. Thornburg, David E. Wentworth, and Bin Zhou

Abstract

The early Omicron lineage variants evolved and gave rise to diverging lineages that fueled the COVID-19 pandemic in 2022. Bivalent mRNA vaccines, designed to broaden protection against circulating and future variants, were authorized by the U.S. Food and Drug Administration (FDA) in August 2022 and recommended by the U.S. Centers for Disease Control and Prevention (CDC) in September 2022. The impact of bivalent vaccination on eliciting neutralizing antibodies against homologous BA.4/BA.5 viruses as well as emerging heterologous viruses needs to be analyzed. In this study, we analyze the neutralizing activity of sera collected after a third dose of vaccination (2-6 weeks post monovalent booster) or a fourth dose of vaccination (2-7 weeks post bivalent booster) against 10 predominant/recent Omicron lineage viruses including BA.1, BA.2, BA.5, BA.2.75, BA.2.75.2, BN.1, BQ.1, BQ.1.1, XBB, and XBB.1. The bivalent booster vaccination enhanced neutralizing antibody titers against all Omicron lineage viruses tested, including a 10-fold increase in neutralization of BQ.1 and BQ.1.1 viruses that predominated in the U.S. during the last two months of 2022. Overall, the data indicate the bivalent vaccine booster strengthens protection against Omicron lineage variants that evolved from BA.5 and BA.2 progenitors.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results